Martin Reck
German Center for Lung Research
Affiliation German Center for Lung Research Top Publications Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer (2018) – 6,794 citations Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC (2018) – 3,828 citations Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden (2018) – 3,196 citations Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung ... <a title="Martin Reck" class="read-more" href="https://journalsworld.com/researchers/martin-reck/" aria-label="Read more about Martin Reck">Read more</a>
Read biography ↓Biography, research & contributions
Affiliation
German Center for Lung Research
Top Publications
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer (2018) - 6,794 citations
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC (2018) - 3,828 citations
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden (2018) - 3,196 citations
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (2019) - 2,914 citations
- Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) - 2,652 citations
At a glance
- Full name
- Martin Reck
- ORCID
- 0000-0002-5348-4462
- OpenAlex ID
- https://openalex.org/A5046728958
Research interests
- Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies, HER2/EGFR in Cancer Research
Research topics
Education
Not yet documented in this profile.
Selected research & further reading
A curated reading list, not a ranking by citation count. References use DOI metadata, matching public scholarly records or authoritative lecture sources.
See the source-linked reading and original works in the research guide above.
Citation & publication trends
Annual counts are not yet available from a verified author record. Explore the research guide above for the work itself; publication and citation totals depend on database coverage.
Source: OpenAlex · Retrieved 2026-10-07. Metrics are database-specific and are not a scientific ranking.
Most-cited linked publications
Publications matched across ORCID and OpenAlex. Citation counts are source-specific.
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer ↗2018 · New England Journal of Medicine6,794OpenAlex citations
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC ↗2018 · New England Journal of Medicine3,828OpenAlex citations
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden ↗2018 · New England Journal of Medicine3,196OpenAlex citations
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer ↗2019 · New England Journal of Medicine2,914OpenAlex citations
- 2,652OpenAlex citations
Recent linked publications
Publications matched across ORCID and OpenAlex. Citation counts are source-specific.
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer ↗2018 · New England Journal of Medicine
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC ↗2018 · New England Journal of Medicine
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden ↗2018 · New England Journal of Medicine
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer ↗2019 · New England Journal of Medicine
Journals published in
No verified record links added yet.
Related publishers
No verified record links added yet.
Institutions
Current verified institution
No verified record links added yet.
Previous institutions
No verified record links added yet.
Awards & honors
Not yet documented in this profile.
Career timeline
Not yet documented in this profile.
Co-authors
No verified record links added yet.
Education & career institution links
No verified record links added yet.
Claim & manage this profile
Are you this researcher? Sign in, provide identity evidence, and request administrator approval. Editing becomes available only after approval.
Sign in to claim this profileSources & data information
Editorial review: 2026-10-07 · Last data update: 2026-10-07 23:43:12
Unknown values are left blank. Linked publications may be a subset of total works. Identity verification, data retrieval and profile ownership are separate checks.